OM:SOBIBiotechs
Assessing Swedish Orphan Biovitrum’s Valuation After New Tryngolza Phase 3 Data And Regulatory Momentum
Fresh trial data on Tryngolza puts Swedish Orphan Biovitrum in focus
Swedish Orphan Biovitrum (OM:SOBI) moved into the spotlight after new pooled subgroup data from the Phase 3 CORE and CORE2 trials showed Tryngolza cut acute pancreatitis risk and lowered triglycerides in severe hypertriglyceridemia.
See our latest analysis for Swedish Orphan Biovitrum.
At a share price of SEK446.6, Swedish Orphan Biovitrum has logged a 35.17% year to date share price return, with momentum building over the...